Tango Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Tango Therapeutics, Inc. (TNGX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $30.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- Tango Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $30.20M, a 29.77% decline from fiscal 2024.
- Tango Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $43.00M, a 32.72% increase from fiscal 2023.
- Tango Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $32.40M, a 2.86% increase from fiscal 2022.
- Tango Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $31.50M, a 69.35% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $30.20M 10-K · filed 2026-03-05 |
| 2024-12-31 | $43.00M 10-K · filed 2025-02-27 |
| 2023-12-31 | $32.40M 10-K · filed 2024-03-18 |
| 2022-12-31 | $31.50M 10-K · filed 2023-03-27 |
| 2021-12-31 | $18.60M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |